Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica

S. S. Wang, M. Schiffman, T. S. Shields, R. Herrero, A. Hildesheim, M. C. Bratti, M. E. Sherman, A. C. Rodriguez, P. E. Castle, J. Morales, M. Alfaro, T. Wright, S. Chen, B. Clayman, R. D. Burk, R. P. Viscidi

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10 049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n = 9949), HPV-18 (n = 9928), HPV-31 (n = 9932), and HPV-45 (n = 3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n = 573). HPV-1 6, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.

Original languageEnglish (US)
Pages (from-to)1248-1254
Number of pages7
JournalBritish journal of cancer
Issue number7
StatePublished - Oct 6 2003


  • Cervical cancer
  • HPV
  • Predictors
  • Seroprevalence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica'. Together they form a unique fingerprint.

Cite this